

Ying-Hong Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3273633/publications.pdf>

Version: 2024-02-01

95
papers

5,055
citations

117571

34
h-index

98753

67
g-index

101
all docs

101
docs citations

101
times ranked

9967
citing authors

#	ARTICLE	IF	CITATIONS
1	Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. <i>Hepatology</i> , 2023, 77, 109-123.	3.6	31
2	<scp>SQSTM1</scp>/p62 in intrahepatic cholangiocarcinoma promotes tumor progression via epithelialâ€mesenchymal transition and mitochondrial function maintenance. <i>Cancer Medicine</i> , 2023, 12, 459-471.	1.3	4
3	CAFs shape myeloidâ€derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5â€lipoxygenase. <i>Hepatology</i> , 2022, 75, 28-42.	3.6	77
4	Serial circulating tumor DNA to predict early recurrence in patients with hepatocellular carcinoma: a prospective study. <i>Molecular Oncology</i> , 2022, 16, 549-561.	2.1	21
5	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 24.	7.1	7
6	A phase Ib, multicenter, open-label study to assess the safety, tolerability, and preliminary efficacy of sintilimab plus IBI310 (anti-CTLA4 mAb) in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 421-421.	0.8	3
7	Targeting HNRNPM Inhibits Cancer Stemness and Enhances Antitumor Immunity in Wnt-activated Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1413-1447.	2.3	15
8	KRAS acting through ERK signaling stabilizes PD-L1 via inhibiting autophagy pathway in intrahepatic cholangiocarcinoma. <i>Cancer Cell International</i> , 2022, 22, 128.	1.8	14
9	Gadoxetate-Enhanced MRI as a Diagnostic Tool in the Management of Hepatocellular Carcinoma: Report from a 2020 Asia-Pacific Multidisciplinary Expert Meeting. <i>Korean Journal of Radiology</i> , 2022, 23, 697.	1.5	4
10	Application of circulating tumor DNA for prediction and surveillance of tumor recurrence after liver transplantation: A pilot study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16149-e16149.	0.8	3
11	Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): A survey of Chinese hepatobiliary surgeons.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16127-e16127.	0.8	1
12	Laparoscopic hepatectomy enhances recovery for small hepatocellular carcinoma with liver cirrhosis by postoperative inflammatory response attenuation: a propensity score matching analysis with a conventional open approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 910-920.	1.3	13
13	Graft Programmed Death Ligand 1 Expression as a Marker for Transplant Rejection Following Antiâ€Programmed Death 1 Immunotherapy for Recurrent Liver Tumors. <i>Liver Transplantation</i> , 2021, 27, 444-449.	1.3	24
14	Laparoscopic vs. Open Repeat Hepatectomy for Recurrent Liver Tumors: A Propensity Scoreâ€Matched Study and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 646737.	1.3	9
15	Prognostic significance of preoperative systemic immune-inflammation index in combined hepatocellular-cholangiocarcinoma. <i>Cancer Biomarkers</i> , 2021, 31, 1-15.	0.8	5
16	Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4099-4099.	0.8	6
17	Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16163-e16163.	0.8	5
18	Abstract 486: A phase Ib/II, open-label study evaluating the efficacy and safety of Toripalimab injection (JS001) or combination with Lenvatinib as a neoadjuvant therapy for patients with resectable hepatocellular carcinoma (HCC). <i>Cancer Research</i> , 2021, 81, 486-486.	0.4	7

#	ARTICLE	IF	CITATIONS
19	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	5.8	90
20	CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 705378.	2.2	17
21	Cystathionine β -synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. , 2021, 9, e003031.		33
22	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 200.	6.9	68
23	Adjuvant chemotherapy for intrahepatic cholangiocarcinoma: far from a clinical consensus. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 887-889.	0.7	3
24	Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2020, 271, 534-541.	2.1	88
25	HNRNPAB-regulated lncRNA-ELF209 inhibits the malignancy of hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2020, 146, 169-180.	2.3	28
26	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. <i>BMC Cancer</i> , 2020, 20, 642.	1.1	9
27	Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1301-1301.	0.7	11
28	Genetic Alterations and Transcriptional Expression of m6A RNA Methylation Regulators Drive a Malignant Phenotype and Have Clinical Prognostic Impact in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 900.	1.3	11
29	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	2.9	10
30	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. <i>Annals of Translational Medicine</i> , 2020, 8, 487-487.	0.7	25
31	MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. <i>Journal of Cancer</i> , 2020, 11, 2476-2484.	1.2	15
32	Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS ICC -applied prediction model. <i>Cancer Science</i> , 2020, 111, 1084-1092.	1.7	14
33	Autophagy and Liver Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1207, 497-528.	0.8	5
34	Effect of postoperative apatinib treatment after resection of hepatocellular carcinoma with portal vein invasion: A phase II study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 514-514.	0.8	3
35	Aspartate aminotransferase-to-platelet ratio index predicts prognosis of hepatocellular carcinoma after postoperative adjuvant transarterial chemoembolization. <i>Cancer Management and Research</i> , 2019, Volume 11, 63-79.	0.9	12
36	A novel very simple laparoscopic hepatic inflow occlusion apparatus for laparoscopic liver surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 145-152.	1.3	6

#	ARTICLE	IF	CITATIONS
37	The miR-561-5p/CX ₃ CL1 Signaling Axis Regulates Pulmonary Metastasis in Hepatocellular Carcinoma Involving CX ₃ CR1 ⁺ Natural Killer Cells Infiltration. <i>Theranostics</i> , 2019, 9, 4779-4794.	4.6	72
38	Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. <i>Theranostics</i> , 2019, 9, 4678-4687.	4.6	61
39	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. <i>Journal of Hepatology</i> , 2019, 71, 1152-1163.	1.8	49
40	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1369-1378.	2.0	12
41	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. <i>Journal of Cancer</i> , 2019, 10, 5575-5584.	1.2	28
42	Development and validation of a new tumor-based gene signature predicting prognosis of HBV/HCV-included resected hepatocellular carcinoma patients. <i>Journal of Translational Medicine</i> , 2019, 17, 203.	1.8	18
43	<p>Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 5187-5195.	0.9	12
44	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. <i>BMC Medicine</i> , 2019, 17, 106.	2.3	31
45	Receptor-Interacting Serine/Threonine-Protein Kinase 3 (RIPK3)â€œMixed Lineage Kinase Domain-Like Protein (MLKL)â€œMediated Necroptosis Contributes to Ischemia-Reperfusion Injury of Steatotic Livers. <i>American Journal of Pathology</i> , 2019, 189, 1363-1374.	1.9	48
46	Tumor-associated macrophages modulate resistance to oxaliplatin via inducing autophagy in hepatocellular carcinoma. <i>Cancer Cell International</i> , 2019, 19, 71.	1.8	92
47	Prognostic alternative mRNA splicing signature in hepatocellular carcinoma: a study based on large-scale sequencing data. <i>Carcinogenesis</i> , 2019, 40, 1077-1085.	1.3	34
48	A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. <i>Hepatology</i> , 2019, 70, 1214-1230.	3.6	140
49	Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection. <i>Journal of Cancer</i> , 2019, 10, 494-503.	1.2	36
50	Laparoscopic Versus Open Left Lateral Segmentectomy for Large Hepatocellular Carcinoma: A Propensity Score-Matched Analysis. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2019, 29, 513-519.	0.4	6
51	Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. <i>Neoplasia</i> , 2019, 21, 1133-1142.	2.3	44
52	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. <i>Aging</i> , 2019, 11, 11111-11123.	1.4	6
53	<scp>SIRT</scp> 5 inhibits peroxisomal <scp>ACOX</scp> 1 to prevent oxidative damage and is downregulated in liver cancer. <i>EMBO Reports</i> , 2018, 19, .	2.0	171
54	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	3.2	102

#	ARTICLE	IF	CITATIONS
55	Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. <i>Oncogene</i> , 2018, 37, 1637-1653.	2.6	125
56	MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. <i>Cancer Letters</i> , 2018, 412, 108-117.	3.2	79
57	SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 243-250.	2.8	16
58	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. <i>Journal of Cancer</i> , 2018, 9, 1025-1032.	1.2	14
59	Autophagy activation contributes to glutathione transferase Mu 1-mediated chemoresistance in hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 16, 346-352.	0.8	12
60	Comparative efficacy and safety between ablative therapies or surgery for small hepatocellular carcinoma: a network meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 935-945.	1.4	13
61	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. <i>Journal of Cancer</i> , 2018, 9, 1106-1112.	1.2	16
62	Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). <i>Liver Cancer</i> , 2018, 7, 235-260.	4.2	426
63	Association of hepatitis status with surgical outcomes in patients with dual hepatitis B and C related hepatocellular carcinoma. <i>Infectious Agents and Cancer</i> , 2017, 12, 28.	1.2	2
64	MicroRNA-29a induces loss of 5-hydroxymethylcytosine and promotes metastasis of hepatocellular carcinoma through a TET-SOCS1-MMP9 signaling axis. <i>Cell Death and Disease</i> , 2017, 8, e2906-e2906.	2.7	66
65	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. <i>BMC Cancer</i> , 2017, 17, 762.	1.1	12
66	Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. <i>BioScience Trends</i> , 2017, 11, 469-474.	1.1	3
67	Shanghai Score. <i>Chinese Medical Journal</i> , 2017, 130, 2650-2660.	0.9	18
68	Inhibition of peritoneal dissemination of colon cancer by hyperthermic CO2 insufflation: A novel approach to prevent intraperitoneal tumor spread. <i>PLoS ONE</i> , 2017, 12, e0172097.	1.1	6
69	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. <i>Oncotarget</i> , 2017, 8, 5135-5148.	0.8	35
70	Prostate-derived ETS factor improves prognosis and represses proliferation and invasion in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 52488-52500.	0.8	10
71	Sequestosome 1/p62 Protein Is Associated with Autophagic Removal of Excess Hepatic Endoplasmic Reticulum in Mice. <i>Journal of Biological Chemistry</i> , 2016, 291, 18663-18674.	1.6	65
72	Nomograms for survival prediction in patients undergoing liver resection for hepatitis B virus related early stage hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2016, 62, 86-95.	1.3	43

#	ARTICLE	IF	CITATIONS
73	FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3/CCL2 Signaling. <i>Cancer Research</i> , 2016, 76, 4124-4135.	0.4	470
74	Destabilization of Fatty Acid Synthase by Acetylation Inhibits <i>De Novo</i> Lipogenesis and Tumor Cell Growth. <i>Cancer Research</i> , 2016, 76, 6924-6936.	0.4	92
75	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. <i>International Journal of Oncology</i> , 2016, 49, 2367-2376.	1.4	39
76	The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. <i>World Journal of Surgical Oncology</i> , 2016, 14, 131.	0.8	25
77	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 169-178.	0.7	32
78	Mitogen-activated protein kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. <i>Hepatology</i> , 2015, 62, 1804-1816.	3.6	33
79	Basal Autophagy and Feedback Activation of Akt Are Associated with Resistance to Metformin-Induced Inhibition of Hepatic Tumor Cell Growth. <i>PLoS ONE</i> , 2015, 10, e0130953.	1.1	14
80	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. <i>Hepatic Oncology</i> , 2015, 2, 231-244.	4.2	13
81	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 846-861.	0.8	84
82	LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 3892-900.	0.5	9
83	Activating Mutations in PTPN3 Promote Cholangiocarcinoma Cell Proliferation and Migration and Are Associated With Tumor Recurrence in Patients. <i>Gastroenterology</i> , 2014, 146, 1397-1407.	0.6	111
84	HNRNPAB Induces Epithelial-Mesenchymal Transition and Promotes Metastasis of Hepatocellular Carcinoma by Transcriptionally Activating <i>SNAIL</i> . <i>Cancer Research</i> , 2014, 74, 2750-2762.	0.4	91
85	High expression of 5-hydroxymethylcytosine and isocitrate dehydrogenase 2 is associated with favorable prognosis after curative resection of hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 32.	3.5	30
86	Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. <i>Autophagy</i> , 2013, 9, 2056-2068.	4.3	222
87	Margin-Infiltrating CD20+ B Cells Display an Atypical Memory Phenotype and Correlate with Favorable Prognosis in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 5994-6005.	3.2	159
88	Intratumoral IL-17+ Cells and Neutrophils show Strong Prognostic Significance in Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 2506-2514.	0.7	87
89	Infiltrating Memory/Senescent T Cell Ratio Predicts Extrahepatic Metastasis of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 455-466.	0.7	43
90	Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. <i>Autophagy</i> , 2011, 7, 1159-1172.	4.3	287

#	ARTICLE	IF	CITATIONS
91	Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin via Reactive Oxygen Species Modulation. <i>Clinical Cancer Research</i> , 2011, 17, 6229-6238.	3.2	162
92	Prognostic significance of Beclin 1-dependent apoptotic activity in hepatocellular carcinoma. <i>Autophagy</i> , 2009, 5, 380-382.	4.3	90
93	Treatment for the recurrence of hepatocellular carcinoma following liver transplantation: What is the best strategy?. <i>Cancer Biology and Therapy</i> , 2009, 8, 591-593.	1.5	2
94	Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. <i>Hepatology</i> , 2008, 48, 497-507.	3.6	95
95	Association of Autophagy Defect with a Malignant Phenotype and Poor Prognosis of Hepatocellular Carcinoma. <i>Cancer Research</i> , 2008, 68, 9167-9175.	0.4	245